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Abstract
Background: Malaria is a public health problem in Uganda; affecting mainly women and children. Effective
treatment has been hampered by over-diagnosis and over-treatment with anti-malarial drugs among patients
presenting with fever. In order to understand the effect of drug pressure on sulfadoxine-pyrimethamine (SP)
resistance in pregnancy, a sample of pregnant women presenting with fever in out–patient clinics was studied. The
main objective was to assess prescription patterns and drug use in pregnancy especially SP; and draw implications
on the efficacy of SP for intermittent preventive treatment of malaria in pregnancy (IPTp).
Methods: A total of 998 pregnant women with a history of fever were interviewed and blood samples taken for
diagnosis of malaria and HIV infections. Data were captured on the drugs prescribed for the current febrile episode
and previous use of drugs especially SP, anti-retroviral drugs (ARVs) and cotrimoxazole.
Results: Few pregnant women, 128 (12.8%) were parasitaemic for P.falciparum; and of these, 72 (56.3%) received
first-line treatment with Artemether-lumefantrine (Coartem®) 14 (10.9%) SP and 33 (25.8%) quinine. Of the parasite
negative patients (non-malarial fevers), 186 (21.4%) received Coartem, 423 (48.6%) SP and 19 (2.1%) cotrimoxazole.
Overall, malaria was appropriately treated in 35.5% of cases. Almost all febrile pregnant women, 91.1%, were
sleeping under a mosquito net. The majority of them, 911 (91.3%), accepted to have an HIV test done and 92 (9.2%)
were HIV positive. Of the HIV positive women, 23 (25.0%) were on ARVs, 10 (10.9%) on cotrimoxazole and 30
(32.6%) on SP. A significant proportion of women, 40 (43.5%), were on both SP and cotrimoxazole. Age and
occupation were associated with diagnosis and treatment of malaria and HIV infections.
Conclusion: There is inappropriate treatment of malaria and non-malarial fevers among pregnant women in these
facilities. This is due to non-adherence to the guidelines. Over-prescription and use of anti-malarial drugs, especially
SP may have implications on resistance against SP for malaria prevention in pregnancy. The policy implications of
these findings are to evaluate SP efficacy as IPTp; and the need to enforce adherence to the current clinical
treatment guidelines.
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Background
Uganda has a high burden of malaria that contributes
greatly to morbidity and mortality [1,2]. Malaria contrib-
utes to 40% of outpatient consultations and 20% inpatient
admissions; and the most vulnerable are women and chil-
dren [1]. The main component of the current malaria
control strategy in Uganda is early diagnosis and effective
case management. In Uganda and elsewhere, effective
treatment has been hampered by the continuing over
diagnosis of malaria and over-treatment with anti-malarial
drugs among patients presenting with a fever particularly
in rural areas where there is poor access to formal health
facilities and self-treatment is the commonest form of care
seeking [3,4].
Malaria in pregnancy is a major public health problem
in malaria endemic areas [5-7]. The current policy in
Uganda for treating malaria in pregnancy in the first tri-
mester is to give quinine 10 m/kg. During the second
and third trimester, ACT are recommended as follows:
Coartem® (artemether 20 mg & lumenfantrine 120 mg)
four tablets twice a day for three days [8]. For malaria
prevention, the policy recommends two doses of SP
as intermittent preventive treatment of malaria in preg-
nancy (IPTp). The rapid spread of P. falciparum para-
sites resistant to SP in malaria endemic areas poses a
major threat to prevention of malaria in pregnancy
[9-11]. There is now evidence of drug resistance to SP
which may have implications for malaria control in preg-
nancy [12-14]. However SP is still the recommended
drug for IPTp in Uganda [15,16]. Thus monitoring
patients for resistant parasites during pregnancy is an
important strategy to provide data for timely policy
review. Recently WHO has issued guidelines on IPTp
for countries in areas of moderate-to high transmission;
IPTp with SP is recommended for all pregnant women
at each scheduled antenatal care visit; and each SP dose
should be given at least 1 month apart [17]. In order to
effectively implement this guideline, it requires continu-
ous monitoring of SP efficacy as IPTp.
In countries with a high HIV prevalence, IPTp with SP has
been found to be less effective thus leading to a recommen-
dation of increasing the number of doses of IPTp in preg-
nancy. Thus in areas of high transmission of P. falciparum,
HIV-positive women are recommended to receive monthly
doses of SP as IPTp rather than the 2-dose regimen [15,16].
The current policy in Uganda is to give trimethoprim-
sulfamethoxazole (cotrimoxazole) prophylaxis for HIV
infected patients. It has been shown that there is cross-
resistance between trimethoprim and pyrimethamine at a
molecular level [17]. It is possible that resistance alleles
may emerge in response to selective pressure imposed by
this treatment regimen [18-21]. In Uganda the policy
doesn’t allow SP and cotrimoxazole to be given together;
except when there is non-adherence to the guidelines.
Previous studies in Uganda have assessed prescription
patterns of drugs in the public and private facilities. In
one study, only 34% of the recommended doses of
chloroquine followed the guidelines [22]. It has been
further shown that only 30% of patients received treat-
ment at a health facility within 24 hours of onset of
symptoms [23]. In another study, polypharmacy was
common in both private and public clinics and there
was over-prescription of anti-malarial drugs and antibi-
otics [24]. Most recently, the commonly prescribed anti-
malarial drugs in rural hospitals of Uganda were ACT
and Quinine [25]. Despite this evidence, few studies have
documented prescription patterns and drug use among
pregnant women with fever visiting clinics in Uganda.
This study aims to answer whether pregnant women
with fever presenting at out-patient clinics get appropri-
ate treatment, what drugs are prescribed and whether
this is according to the guidelines.
Understanding treatment patterns for febrile illness
among pregnant women in countries endemic for mal-
aria is of public health importance for three reasons:
1) to gain an understanding of factors associated with
treatment seeking among this vulnerable group and de-
sign interventions to increase access to effective treat-
ment and prevention of malaria and other non-malarial
fevers; 2) drugs given in pregnancy may have direct and
indirect effects on the baby; 3) to understand the level of
appropriate treatment since inappropriate drug use may
lead to drug resistance. The main objective of this study
was to assess prescription patterns and drug use among
pregnant women with fever. Specifically the study assessed
use of anti-malarial drugs during the current and previous
febrile episodes; and use of SP and cotrimoxazole among
HIV positive women. This article presents results on drug
use among a sample of pregnant women presenting with
fever at out-patient clinics in Uganda. Implications of the
results and further areas of research are discussed.
Methods
Study area and population
The study was conducted in the malaria endemic district
of Mukono, central Uganda. The total population of the
district is 850,900 with an annual growth rate of 2.3%
and consists predominantly of subsistence farmers of the
Baganda ethnic group. The majority of the population,
88%, lives in the rural areas.
Study design
A survey targeting pregnant women presenting with fever
in out–patient clinics was carried out from January to
November 2011. Inclusion criteria were: i) Actual fever or
history of fever during the last 14 days, ii) temperature at
least 37.5°C; this was taken using a digital thermometer
iii) menstrual history and a clinical examination by a
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trained midwifes and clinical officers to confirm a preg-
nancy. A structured questionnaire was administered to all
eligible consenting pregnant women with fever attending
outpatient clinics over a period of 10 months. The ques-
tionnaire captured data on demographic characteristics,
history of febrile illness, treatment received, HIV counsel-
ling and testing practices, history of taking SP, antimalarial
drugs, ARVs and other drugs. Midwives working in two
maternity units at Kawolo hospital and Mukono health
centre IV conducted the interviews and patients who
consented to give a blood sample were sent to a labora-
tory. The midwives were trained for 2 days on study pro-
cedures and they participated in the pre-testing and
reviewed the tools before the study. Questionnaires were
initially developed in English and translated into the local
language (Luganda). The field coordinator and the re-
search team supervised all aspects of data collection.
Laboratory methods
Blood (4 mls) was taken by venepuncture from every pa-
tient who consented to the study and stored in EDTA
tubes. Haemoglobin, HIV and malaria infections and
were assessed. Smears were stained with Giemsa and
malaria parasites were counted against 200 leukocytes
and expressed as number of parasites per μl of blood as-
suming a standard leukocyte count of 8000/μl of blood.
A blood smear was regarded negative after examining a
minimum of 100 high power fields with no parasites
seen. This is because the study area is known to be highly
endemic for malaria thus the selection of this cut-off point.
All buffers, solutions and stains were stored appropriately
and cleanliness and sterility of equipment maintained. For
quality assurance, all malaria positive samples examined in
the field laboratory were re-examined at the reference la-
boratory at the Uganda Virus Research Institute. Discrep-
ancy between the two readings was less than 5%.
HIV test was performed following the national algo-
rithm on HIV testing. A blood sample undergoes three
tests: the first is Determine® and if positive, it is con-
firmed by Statpak® if still positive by Unigold®. Results
were recorded on forms and clients told the results.
Statistical analyses
Data was entered and verified using Microsoft Access 2007
(Microsoft Inc., Redmond, Washington) and analysed
using STATA version 11.0 (STATA Corporation, College
Station, Texas). Univariate analyses were carried to get the
proportions of drugs prescribed to women with malaria,
non-malaria fevers and those who were HIV positive. Bi-
variate analysis was carried to assess factors associated with
diagnosis and treatment of malaria and HIV infections.
Proportions were compared using a chi-Square test and
P-values <0.05 were considered significant. Appropriate
treatment was calculated as the number of parasite positive
pregnant women who received Coartem® plus parasite
negative women who received no antimalarial drug divided
by the total number of febrile cases. The sample size calcu-
lation was based on the proportion of pregnant women ap-
propriately treated for malaria estimated at 25% [26]. The
study aimed to detect a difference of 4% in this proportion
at 80% power and 5% level of significance; and the number
of patients to estimate this difference was 946. Allowing a
5% for non-response rate, the minimum number of pa-
tients was 993.
Ethics
Ethical approval for the research was granted by review
boards at the Uganda National Council of Science and
Technology (Reference HS. 747). Written consent was
obtained from all participating women.
Results
Patient characteristics
A total of 998 pregnant women presenting with fever
were included in the study. The mean age was 23.9 years
with a range of 14–42 years. The majority of women,
64.9%, were aged between 20–29 years, 33.7% had
attained secondary education and 78.2% were married;
while 47.7% were peasants earning from household agri-
cultural activities (Table 1).
Table 1 Background characteristics of women pregnant
women with fever attending outpatient clinics

















Peasant /agriculture 472 (47.3)
Employed 132 (12.3)
Business/shop 276 (27.7)
Some activity that earns money 108 (10.8)
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Febrile illnesses among pregnant women and treatment
received
Of the pregnant women presenting with fever, only 128
(12.8%) had parasitaemia. Of these, 72 (56.3%) received
the first-line antimalarial drug, Coartem®. A large pro-
portion 33 (25.8%) received quinine while 14 (10.9%)
received SP (Fansidar®). Among pregnant women with
no malaria parasites, 186 (21.4%) were given Coartem®
and 423 (48.6%) Fansidar® (SP); 113 (13.0%) were given
antibiotics. Appropriate treatment of malaria (patients
with malaria receiving first-line drug (ACT) and patients
without malaria receiving no antimalarial drug) occurred
in 35.5% of pregnant women. The majority of patients
909 (91.1%) were sleeping under a mosquito net (Table 2).
HIV/AIDS testing and treatment received
The majority of pregnant women in this study were will-
ing to have an HIV test done, 911 (91.3%) (Table 3);
while 361 (36.2%) had had a test prior to this visit. Ado-
lescents were less likely to have had a previous HIV test,
88 (13.9%) compared to 547 adults (86.1%), P = 0.0001
(data not shown). Among the pregnant women who had
an HIV test, 92 (9.2%) were HIV positive. A quarter,
(25.0%) of HIV positive women were on ARVs, while 30
(32.6%) of them were taking cotrimoxazole. Forty HIV
positive women (43.5%) were taking both cotrimoxazole
and SP (Table 3).
Factors associated with diagnosis and treatment of
malaria and HIV
We explored factors associated with diagnosis and treat-
ment of malaria and HIV. Younger women were likely
to test positive for malaria, mean age 22.3 years versus
24 years for negative women, P = 0.0002; and receiving
anti-malarial treatment, P = 0.02. Similarly occupation,
P = 0.004; and tribe, P = 0.02 were associated with re-
ceiving anti-malarial treatment. HIV positivity was asso-
ciated with age (mean age 23.7 years for HIV negative
versus 24.9 years for positive women, P = 0.02); and
access to ARVs (mean age 23.9 years for HIV negative
versus 25.9 years for HIV positive women, P = 0.02).
Education, marital status and religion were not associ-
ated with diagnosis and treatment of malaria and HIV
infections in this population.
Discussion
This study shows that there is inappropriate treatment
of malaria among pregnant women with fever attending
outpatient clinics. Although ACT are the first-line anti-
malarial drug, many patients with confirmed malaria
were not given ACT but SP. This may lead to parasite
resistance to SP. Similarly, inappropriate use of ACT in
pregnant women with non-malarial fevers may also lead
Table 2 Prevalence of febrile illnesses among pregnant
women attending outpatient clinics
Patient characteristics Frequency
(%)
Duration of current febrile episode (days) N = 998
1–6 days 858 (86.0)




Treatment given to patients with confirmed malaria N = 128
Coartem 72 (56.3)
Fansidar (SP) 14 (10.9)
Quinine 33 (25.8 )
Paracetamol 1 (0.8)
Antibiotic 8 (6.2)
Treatment of non-malarial fevers N = 870
Chloroquine 45 (5.2 )
Coartem 186 (21.4)
Fansidar (SP) 423 (48.6)




Appropriate treatment of malaria
Parasite positive patients who received
Coartem + parasite negative patients
who received no antimalarial drug/total
number of febrile cases
35.5%
Malaria treatment and preventive practices N = 998
Proportion of patients who had taken an anti-malaria
drug before this visit
313 (31.4)
Proportion of patients who slept under a net the
previous night
909 (91.1)
Proportion of patients who sleep under a net every day 892 (89.4)
Table 3 HIV/AIDS prevention and treatment practices
Patient characteristics Frequency (%)






Treatment/prevention of HIV/AIDS N = 92
HIV positive patents on ARVs 23 (25.0)
HIV positive patents on cotrimoxazole 10 (10.9)
HIV positive patents on SP 30 (32.6)
HIV positive patents on cotrimoxazole and SP 40 (43.5)
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to resistance against these drugs. These results will con-
tribute to the design of a further study to evaluate the ef-
ficacy of SP as IPTp in Uganda.
A recent study in health facilities in Uganda found out
that there were constraints to parasite diagnosis like lack
of microscopes and RDTs, inadequate personnel and in-
frastructure. This scenario impacts on appropriate treat-
ment of malaria and other diseases. Similarly a study in
Jinja, a neighbouring district in Eastern Uganda showed
that 85% of self-reported febrile illnesses were treated
with antimalarial drugs [27].
The present results compare with those from a study
carried out in South-Western Uganda in an area of low
malaria endemicity which found high prescription rates
for antibiotics in febrile patients, the majority of whom
were children aged less than 5 years, and concluded that
testing negative for malaria increases the use of antibi-
otics [25]. The present study, however, shows that anti-
biotic prescription among febrile patients was low and
this is likely because these were adult patients and the
risk of pneumonia could have been low. It is also pos-
sible that health workers may not be thinking of com-
mon diseases in pregnancy that may require antibiotics.
A diagnosis and treatment alogorithm for helping health
workers to treat malaria and other common diseases is
recommended and could include confirming pregnancy
and the gestation period; checking urine for infections,
HIV testing, screening for lung infections and history of
anti-malarial drugs especially of SP.
Our study shows that access to ACT is high, consistent
with findings from another Ugandan study that the most
commonly prescribed antimalarial drugs are artemether-
lumefantrine and quinine with a relatively high adherence
to the new antimalarial treatment policy [28]. This con-
trasts with an earlier study conducted across six African
countries that showed poor access to ACT in Benin
(10%), DRC (5%), Madagascar (3%), Nigeria (5%), Uganda
(21%) and Zambia (21%) [26]. Increased access to ACT in
Uganda is attributed to a recent government initiative
through the Global Fund that supports local manufactur-
ing of ACT and ARVs. Access and use of ARVs is however
poor as noted in our results due to inadequate laboratory
services to analyze CD4 count, a pre-requisite to start pa-
tients n ARVs.
In interpreting the results it is worth noting that this
study targeted pregnant women with fevers reporting in
outpatient clinics thus the drug use and prescription pat-
terns in other groups were not included. Clinical exam-
ination was relied to estimate the gestation period and
thus could have missed pregnancies in the first trimester.
In addition, the study was limited in the capacity to
identify the causes of non-malaria fevers. A study
carried on Thai-Burmese border found that non-malaria
fevers in pregnancy were mainly scrub and typhus fevers
[29]. Since such infections are not common in Uganda,
it would be of interest to have a study to document the
causes of non-malaria fevers among pregnant women in
Uganda. This study looked at fever in pregnancy; however
diagnosis of malaria in pregnancy is problematic since
most pregnant women in highly endemic areas have im-
munity, are asymptomatic and peripheral blood may not
show parasitaemia [30]. Thus this study may have under-
estimated the magnitude of malaria in pregnancy.
The implications of these results are to ensure that
health workers adhere to laboratory test results and
prescribe according to the treatment guidelines. This will
ensure appropriate treatment and avoid indiscriminate
drug use potentially leading to drug resistance. Printing
and distributing treatment guidelines supported by tech-
nical supervision are urgently needed to address this
situation. Further areas for research include evaluating
the efficacy of SP as IPTp and the review of the guidelines
for IPTp among HIV positive women since interaction of
SP with cotrimoxazole could hamper the effectiveness of
SP. There is also need to strengthen pharmacovigilance of
antimalarial drugs to enable timely review of policies.
Conclusions
There is inappropriate treatment of malaria and non-
malarial fevers among pregnant women in these facilities.
This is due to non-adherence to the guidelines. Over-
prescription and use of anti-malarial drugs, especially SP
may have implications on resistance against SP for malaria
prevention in pregnancy. The policy implications of these
findings are to evaluate SP efficacy as IPTp; and the need
to enforce adherence to the current clinical treatment
guidelines.
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